A Phase 2 Study of Trametinib for Patients With Pediatric Glioma or Plexiform Neurofibroma With Refractory Tumor and Activation of the MAPK/ERK Pathway.
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 29 Jan 2018
At a glance
- Drugs Trametinib (Primary)
- Indications CNS cancer; Glioma; Neurofibromatoses; Plexiform neurofibroma
- Focus Therapeutic Use
- 22 Jan 2018 Planned initiation date changed from 1 Jan 2018 to 1 Mar 2018.
- 08 Dec 2017 New trial record